CStone Pharmaceuticals (FRA:PH4) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PH4 CStone Pharmaceuticals FRA:PH4
55 GF Score
Price €0.48
GF Value €0.12
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is CStone Pharmaceuticals FFO per Share?

FFO per Share only applies to REITs.

FRA:PH4
55GF Score
CStone Pharmaceuticals FRA:PH4
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is CStone Pharmaceuticals (FRA:PH4) Overvalued in 2026?

Based on GuruFocus' analysis, CStone Pharmaceuticals stock appears to be overvalued. The current stock price of €0.48 is trading 302.3% above its estimated GF Value™ of €0.12. GuruFocus considers CStone Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:PH4:

  • FFO per Share:
  • GF Value™: €0.12 vs. price of €0.48 (302.3% above fair value)
  • GF Score™: 55/100 with 7 warning signs

No single metric tells the full story. See the FRA:PH4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CStone Pharmaceuticals Business Description

Address 218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Suzhou, CHN, 215123
CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The Group has been operating in one reportable segment, being the research and development of high-complex biopharmaceutical products, the sale of pharmaceutical products, and provide license of its IP or commercialisation licenses to customers.
55GF Score

Get the complete analysis for FRA:PH4

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.48
Price
€0.12
GF Value